OUR LEADERSHIP

… is focused on delivering solutions for the advancement of human health. Founded on science, driven by passion, and guided by meritocracy, it will shape the development and acceptance of patient-friendly medicines.

OUR MANAGEMENT TEAM

… stewards for impact and transformative societal change guided by the spirit of innovation, principles of governance, with servitude to patients, shareholders and stakeholders.

Ahmad Doroudian, PhD

Moira Ong, CPA, CA
Chief Executive Officer & Director
  • 20+ years experience as a Pharma CEO in finance, including M&A, and multiple IPOs, integration of pharmaceutical operations (Whitehall Robbins, Rhone Polenc, Boehringer, Aventis)
  • Founder of Merus Labs (NASDAQ: MSLI), sold for $300 M+ in 2017
  • Acquisition, integration, tech transfer and management of branded pharmaceutical products Enablex®/Emselex®, Entrophen®, Sandomigran®, Sintrom®, Vancocin®, Zaditen®

Hooshmand Sheshbaradaran, PhD

Hooshmand Sheshbaradaran, PhD
Chief Operating Officer
  • 30+ years senior pharma executive with experience in global drug development, marketing, business strategy, operations, licensing and M&A
  • Senior executive roles at Pharmacia/Pfizer, Roche, Zeneus/Cephalon, Niiki Pharma, Psioxus
  • Development of Camptosar®, Ellence®, Emcyt®, Sutent® and Vidaza®.

Moira Ong, CPA, CA

Moira Ong, CPA, CA Chief Financial Officer
Chief Financial Officer
  • 20+ years experience in financial reporting, compliance and audit.
  • Managed the integration of the supply chain management and accounting for Vancocin, Enablex®/Emselex®, acquired from Novartis, by Merus Labs International Inc. (formerly NASDAQ: MSLI)
  • Previously at Grant Thornton, Deloitte & Touche and Hay & Watson Chartered Professional Accountants

Scott Rudge, PhD

Scott Rudge, PdD
Head CMC
  • Founded CMC development expert services group in 2004, has worked on over 200 projects for all molecule/therapy classes since
  • Site Director & VP Operations for FeRx; increasing management responsibility at NIST, Synergen, Amylin
  • PhD in Chemical Engineering from Purdue and author of multiple peer reviewed articles, book chapters and an award-winning textbook

Abdi Ghaffari, PhD

Abdi Ghaffari, PhD
Head Preclinical & Toxicology
  • 15+ years pharma executives with experience in nonclinical pharmacology and toxicology in fields of neuropsychiatric disorders, oncology, and respiratory infection.
  • senior scientist roles at PulmoNOx, Beyond Air, Novateur, and Tika Therapeutics.

Anthony Calandra, PhD

Head Regulatory
  • Ph.D. with 30+ years of pharmaceutical and regulatory affairs experience in strategic and increasingly responsible managerial positions
  • Proven track record of successful IND submissions and NDA and BLA approvals
  • Long track record of successful negotiations with multiple FDA divisions
OUR SCIENTIFIC ADVISORS / COLLABORATORS

… work with thorough multi-disciplinary skill sets, as the vanguard to create, develop, test and advance discoveries for the needed solutions.

Dr. Mark Swaim, MD, PhD

Moira Ong, CPA, CA
  • Mark is editor-in-chief and founder of BioPub, a small-cap biotech investing situations analysis website with a global following.
  • He graduated summa cum laude from University of North Carolina with a chemistry and was a rare junior-year inductee into Phi Beta Kappa.
  • In the NIH-sponsored Medical Scientist Training Program at Duke University, he earned an MD with junior election to Alpha Omega Alpha and a PhD in biochemistry and cell biology with special distinction.
  • He trained in categorical internal medicine at Duke, completed post-doctoral work in distintegrins at National Taiwan University (Taipei), and returned to Duke for research and clinical fellowships in gastroenterology and transplant hepatology.
  • After serving on the faculties of Duke, where he was awarded the medical center’s highes teaching honor, and later University of Texas MD Anderson Cancer Center (Houston), where he was elected to the faculty senate, and UT Health Science Center in Houston, he established an independent freestanding hepatology clinic and clinical research institute, leading clinical trials for a large number of pharma companies and speaking nationally on interferon therapeutics for virus hepatitis as a key opinion leader for many years.
  • He authored more than three dozen peer-reviewed publications and chapters, over 100 abstracts, and was elected Fellow of the American College of Physicians in 2002.
  • With an impressive record of success in biotech investing and analysis, and the growing success of BioPub, he decided to devote all energies to guiding biotech investors, analyzing investing situations, and serving as a consultant to the biotech industry.

Dr. Thomas P. Laughren, MD

Moira Ong, CPA, CA
  • Dr. Thomas Laughren is currently a consultant in psychiatric and neurologic drug development.
  • He retired as Division Director for the Division of Psychiatry Products, Center for Drug Evaluation and Research at FDA in December 2012.
  • Prior to coming to FDA in September 1983, Dr. Laughren was affiliated with the VA Medical Center in Providence, RI, and was on the faculty of the Brown University Program in Medicine.
  • He received his medical degree from the University of Wisconsin in Madison, Wisconsin, and completed residency training in psychiatry at the University of Wisconsin.
  • As Division Director for the Division of Psychiatry Products, Dr. Laughren oversaw the review of all psychiatric drug development activities conducted under INDs and the review of all NDAs and supplements for new psychiatric drug claims.
  • He has authored and co-authored many papers and book chapters on regulatory and methodological issues pertaining to the development of psychiatric drugs and is a frequent speaker at professional meetings on these same topics. Dr. Laughren has received numerous awards for his regulatory accomplishments.

Dr. Adam Halberstadt

Dr. Adam Halberstadt

Associated Professor Psychiatry UC San Diego

Dr. John McCorvy

Dr. John McCorvy

Assistant Professor Dept. Neurobiology

Medical College of Wisconsin

Dr. Argel Aguilar-Valles

Dr. Argel Aguilar-Valles

Assistant Professor Dept. Neuroscience

Carlton University

Dr. Nader Ghasemlou

Dr. Nader Ghasemlou

Assistant Professor School of Medicine

Queen’s University

OUR BOARD OF DIRECTORS
… brings accomplished, diverse, noble, and fostered set of experiences important to effect change with prudency, purpose, and passion while managing challenges.

Ahmad Doroudian, PhD

Moira Ong, CPA, CA
  • 20+ years experience as a Pharma CEO in finance, including M&A, and multiple IPOs, Integration of pharmaceutical operations (Whitehall Robbins, Rhone Polenc, Boehringer, Aventis)
  • Founder of Merus Labs (NASDAQ: MSLI), sold for $300 M+ in 2017
  • Acquisition, integration, tech transfer and management of branded pharmaceutical products Enablex®/Emselex®, Entrophen®, Sandomigran®, Sintrom®, Vancocin®, Zaditen®

Robert Metcalfe

Moira Ong, CPA, CA
  • Served as president, chief executive officer, lead director, chairman and committee member on numerous publicly listed natural resource and industry company corporate boards in Canada, the USA, England, South America and Africa
  • Senior partner with the law firm, Lang Michener LLP, for 20 years
  • Engaged in numerous acquisitions, divestitures, corporate reorganizations, financings and corporate improvements, as well as serving on numerous special committees across many sectors

Ralph Anthony Pullen

Moira Ong, CPA, CA
  • Investment banker in the healthcare and biotechnology industry sectors
  • Instrumental in the creation and funding of MDS Capital Corp., Canada’s largest venture capital fund dedicated to the life sciences, now known as Lumira Capital where he served as a board member

Wolfgang Renz

Moira Ong, CPA, CA
  • President of International Business at Physicians Interactive
  • Formerly served as Corporate Vice President of Business Model & Healthcare Innovation at Boehringer Ingelheim, one of the world’s largest pharmaceutical companies
  • 10+ years involvement in developing medicines and technology to help people lead healthier, more productive lives
OUR INDUSTRY PARTNERS
… are frontiers for explicit life changing discoveries for paradigms that impact patient needs today
and effect societal adoptions tomorrow.

AIRD McBURNEY

eurofins Discovery

eurofins CDMO

MD Biosciences

Neva Analytics

Nucro Technics

RMC Pharma

INVESTOR OVERVIEW

BetterLife Investor Presentation

Working to Build a BetterLife, with innovate medicines.

 

Our work delivers patient-friendly medicines to rejuvenate and restore the health of the mind and the body.

 
Email us: ir@blifepharma.com
 

Follow us: